Why I Would Buy AstraZeneca PLC And Sepura Plc But Sell Vedanta Resources plc

Royston Wild runs the rule over AstraZeneca PLC (LON: AZN), Sepura Plc (LON: SEPU) and Vedanta Resources plc (LON: VED).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at why I would — or would not — invest in these three FTSE-listed businesses.

AstraZeneca

Another week, another rush to the exits at AstraZeneca (LSE: AZN) (NYSE: AZN.US) as investors fret over yet more bad news on the competition front. Tests on industry rival Merck’s diabetes drug Januvia showed that the drug did not increase the chances of heart failure, unlike AstraZeneca’s own Onglyza treatment which has suffering from enduring fears over potential cardiovascular side-effects.

Shares in the London firm have shed 9% in little over a week, as of course news of competitors’ products gaining an advantage on those of AstraZeneca, not to mention the rolling issue of exclusivity losses on critical labels, remains big news. However, investors should not lose sight of the excellent progress the drugs giant’s rejuvenated pipeline is making — AstraZeneca has received a slew of positive late-stage data since the start of the year — as well exploding revenues growth in emerging markets. Sales to these regions leapt 18% during January-March.

AstraZeneca is not expected to get back into the black just yet, although City forecasts of further earnings slips to the tune of 1% in 2015 and 2016 mark a vast improvement from the dips of recent years. Indeed, I believe that the company’s back-breaking R&D overhaul of recent years should propel earnings markedly higher looking further ahead, making P/E multiples of 16.8 times for 2015 and 17.1 times for 2016 decent value for money.

Sepura

Communications specialist Sepura (LSE: SEPU) has been one of the standout performers in end-of-week business and was recently dealing 9.2% higher on the day. The firm has been buoyed by news that it shelled out €127.5m to acquire Spain’s Teltronic, whose exceptional voice and data communications services gives Sepura terrific exposure to the US and Latin America.

Sepura reported this month that revenues leapt 11% during the year concluding March 2015, to €130m, while its order book has also leapt to record levels. And of course today’s deal boosts its sales prospects in hot growth regions still further, leaving it in great shape to enjoy further double-digit earnings growth in the coming years.

The City expects Sepura to punch bottom line expansion of 16% in fiscal 2016, and to follow this up with a 13% advance the following year. These forecasts drive a P/E multiple of 15.4 times for this year to 13.4 times in 2017 — comfortably below the watermark of 15 times which indicates great value — while a PEG readout of 1 through to the close of next year further underlines Sepura’s ultra-cheap share price.

Vedanta Resources

Like Sepura, Vedanta Resources (LSE: VED) has also enjoyed a bounce in Friday trading and was last changing hands 4.2% higher on the day. But unlike the tech play, I believe that ongoing questions over the state of the natural resources markets makes the digger a particularly-perilous selection for stock hunters.

The mining colossus was forced to swallow a $3.1bn writedown on oil explorer Cairn India, in which Vedanta secured a majority stake in 2011, due to the effect of collapsing crude prices.

And with swathes of new oil production still hitting the market, and other key segments such as iron ore and aluminium also suffering from worsening supply/demand imbalances, I believe that earnings could continue to take a whack — group EBITDA dropped 13% during the 12 months to March 2015.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »